PLYX News & Events

Polaryx Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis, Krabbe disease, and Sandhoff disease. "We are delighted by the FDA's decision to further extend Fast Track Designation to CLN3, Krabbe disease, and Sandhoff disease," said Alex Yang, Chair and Chief Executive Officer of Polaryx Therapeutics. "As we prepare to advance the SOTERIA Phase 2 basket trial, receiving this designation across all four indications underscores the enormous need that exists in the current LSD landscape while also recognizing PLX-200's potential to meaningfully address treatment gaps across multiple LSDs."

Polaryx announced that the FDA has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis, or LINCL/CLN2 disease. The Fast Track program is designed to facilitate and expedite the review of therapies intended to treat serious or life-threatening conditions with unmet medical need. Companies receiving Fast Track designation may benefit from more frequent interactions with the FDA and the potential for rolling review of a future marketing application.

Polaryx Therapeutics, Inc trading halted, volatility trading pause